Previous close | 134.14 |
Open | 134.14 |
Bid | 142.80 |
Ask | 147.80 |
Strike | 770.00 |
Expiry date | 2025-01-17 |
Day's range | 134.14 - 134.14 |
Contract range | N/A |
Volume | |
Open interest | 29 |
Insightful Analysis of Regeneron's Financials and Strategic Positioning
Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea.
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.